Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study

被引：2

作者：

Chisari, Clara G. ^{[1
,2
]}

Aguglia, Umberto ^{[3
]}

Amato, Maria Pia ^{[4
,5
]}

Bergamaschi, Roberto ^{[6
]}

Bertolotto, Antonio ^{[7
]}

Bonavita, Simona ^{[8
]}

Morra, Vincenzo Brescia ^{[9
]}

Cavalla, Paola ^{[10
]}

Cocco, Eleonora ^{[11
]}

Conte, Antonella ^{[11
,12
,13
]}

Cottone, Salvatore ^{[14
]}

De Luca, Giovanna ^{[15
]}

Di Sapio, Alessia ^{[6
,7
]}

Filippi, Massimo ^{[16
,17
,18
,19
,20
]}

Gallo, Antonio ^{[7
,8
]}

Gasperini, Claudio ^{[21
]}

Granella, Franco ^{[22
]}

Lus, Giacomo ^{[23
]}

Maimone, Davide ^{[24
]}

Maniscalco, Giorgia Teresa ^{[25
]}

Marfia, Girolama ^{[26
]}

Moiola, Lucia ^{[17
]}

Paolicelli, Damiano ^{[27
]}

Pesci, Ilaria ^{[28
]}

Ragonese, Paolo ^{[29
]}

Rovaris, Marco ^{[30
]}

Salemi, Giuseppe ^{[29
]}

Solaro, Claudio ^{[31
]}

Totaro, Rocco ^{[32
]}

Trojano, Maria ^{[33
]}

Vianello, Marika ^{[34
]}

Zaffaroni, Mauro ^{[35
]}

Lepore, Vito ^{[36
]}

Patti, Francesco ^{[1
,2
]}

机构：

[1] Univ Catania, Sect Neurosci, Catania, Italy

[2] Univ Catania, UOS Sclerosi Multipla, AOU Policlin G Rodol San Marco, Catania, Italy

[3] Great Metropolitan Bianchi Melacrino Morelli Hosp, Reg Epilepsy Ctr, Reggio Di Calabria, Italy

[4] Univ Florence, Sect Neurosci, Dept NEUROFARBA, Florence, Italy

[5] IRCCS Fdn Don Carlo Gnocchi, Florence, Italy

[6] IRCCS Mondino Fdn, Pavia, Italy

[7] AOU San Luigi Gonzaga, Multiple Sclerosis Reg Referral Ctr, Dept Neurol, Turin, Italy

[8] Univ Campania Luigi Vanvitelli, Dept Adv Med & Surg Sci, Naples, Italy

[9] Univ Federico II, Multiple Sclerosis Ctr, Naples, Italy

[10] City Hlth & Sci Univ Hosp Torino, Multiple Sclerosis Ctr, Dept Neurosci & Mental Hlth, Turin, Italy

[11] ATS Sardegna Univ Cagliari, Multiple Sclerosis Ctr, Binaghi Hosp, Cagliari, Italy

[12] Sapienza Univ Rome, Dept Human Neurosci, Rome, Italy

[13] IRCCS Neuromed Pozzili, Pozzilli, Italy

[14] ARNAS Civico, Dept Neurol, Palermo, Italy

[15] Univ G dAnnunzio, Multiple Sclerosis Ctr, Neurol Clin, Policlin SS Annunziata, Chieti, Pescara, Italy

[16] IRCCS San Raffaele Sci Inst, Div Neurosci, Neuroimaging Res Unit, Milan, Italy

[17] IRCCS San Raffaele Sci Inst, Neurol Unit, Milan, Italy

[18] IRCCS San Raffaele Sci Inst, Neurorehabil Unit, Milan, Italy

[19] Univ Vita Salute San Raffaele, Milan, Italy

[20] IRCCS San Raffaele Sci Inst, Neurophysiol Serv, Milan, Italy

[21] San Camillo Forlanini Hosp, UOC Neurol, Dept Neurosci, I-00152 Rome, Italy

[22] Univ Parma, Dept Med & Surg, Neurosci Unit, Parma, Italy

[23] Univ Campania L Vanvitelli, Multiple Sclerosis Ctr, Dept Adv Med & Surg Sci, Div Neurol 2, Naples, Italy

[24] UOC Neurol, Ctr Sclerosi Multipla, Azienda Osped Cannizzaro, Catania, Italy

[25] Cardarelli Hosp, Multiple Sclerosis Ctr, Naples, Italy

[26] Tor Vergata Univ, Dept Syst Med, Multiple Sclerosis Clin & Res Unit, Rome, Italy

[27] Univ Bari A Moro, Dept Translat Biomed & Neurosci, Bari, Italy

[28] Osped Vaio, Ctr Sclerosi Multipla Unit Operativa Neurol, Azienda Unit Sanit Locale, Fidenza, Parma, Italy

[29] Palermo Univ, Dept Biomed Neurosci & Adv Diagnost, Unit Neurol, Palermo, Italy

[30] IRCCS Don C Gnocchi Fdn ONLUS, Milan, Italy

[31] CRRF Mons L Novarese, Rehabil Dept, Moncrivello, VC, Italy

[32] Univ Aquila, Demyelinating Dis Ctr, Neurol Unit, Laquila, Italy

[33] Univ Aldo Moro, Sch Med, Bari, Italy

[34] Ca Foncello Hosp, OU Neurol, Treviso, Italy

[35] Osped Gallarate, Multiple Sclerosis Ctr, ASST Valle Olona, Gallarate, VA, Italy

[36] Ist Ric Farmacolog Mario Negri IRCCS, Milan, Italy

来源：

NEUROTHERAPEUTICS | 2024年 / 21卷 / 04期

关键词：

Natalizumab; Interferon beta 1b; Secondary progressive multiple sclerosis; Disability progression; EUROPEAN MULTICENTER TRIAL; INTERFERON BETA-1B; DISABILITY; DISEASE; RELAPSE; CXCL13; EDSS; MS;

D O I：

10.1016/j.neurot.2024.e00363

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Treatment options for secondary progressive MS (SPMS) are limited, especially considering that the new drugs recently approved are licensed for actively relapsing patients. We aimed to compare the disability progression in a real-world cohort of SPMS patients treated with natalizumab (NTZ) or interferon beta-1b (IFNb-1b). This multicenter retrospective enrolled patients with a diagnosis of SPMS according to 2014 Lublin criteria, who received NTZ or IFNb-1b for at least 48 months between the 1st June 2012 and the 15th May 2018 at 33 Italian MS centers contributing to the Italian MS Registry NTZ or IFNb-1b. Confirmed Expanded Disability Status Scale worsening (CEW) and progression independent of relapse (PIRA) were evaluated. In order to correct for nonrandomization, a propensity score matching of the groups was performed. Out of 5206 MS patients identified at the time of data extraction, 421 SPMS patients treated with NTZ (224 [53.2%] females, mean age 45.3 +/- 25.4 years) and 353 with IFNb-1b (133 [37.8%] females, mean age 48.5 +/- 19.8 years) were enrolled. After applying the matching procedure, 102 patients were retained in the NTZ group and 98 in the IFNb-2b group. The proportion of patients who reached the 48-month 1-point CEW was significantly higher in IFNb-1b compared to NTZ group (58.2% versus 30.4%, p = 0.01). The proportion of patients who developed PIRA at 48 months were significantly higher in IFNb-1b compared to NTZ (72.4% versus 40.2%, p = 0.01). EDSS before treatment initiation and SPMS duration were risk factors for disability progression in terms of PIRA (HR 2.54, 25%CI 1.67 -5.7; p = 0.006 and HR 2.04, 25%CI 1.22 -3.35; p = 0.01, respectively). Patients treated with IFNb-1b were 1.64 times more to likely to develop PIRA (HR 1.64, 25%CI 1.04 -4.87; p = 0.001). Treatment with NTZ in SPMS patients showed more favorable disability outcomes compared to IFNb-1b with beneficial effects over 48 months.

引用

页数：8

共 50 条

[21] Short and Long-Term Outcomes of Epidural or Intravenous Analgesia after Esophagectomy: A Propensity-Matched Cohort Study
Li, Wei
Li, Yongchun
Huang, Qingyuan
Ye, Shengquan
Rong, Tiehua
PLOS ONE, 2016, 11 (04):
[22] Long-Term Outcomes After Thoracoscopic Resection of Stage I and II Thymoma: A Propensity-Matched Study
Chao, Yin-Kai
Liu, Yun-Hen
Hsieh, Ming-Ju
Wu, Yi-Cheng
Chen, Tzu-Ping
Lu, Ming-Shian
Lu, Hung-I
Liu, Hui-Ping
ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (04) : 1371 - 1376
[23] Progression to disability milestones in multiple sclerosis with long-term natalizumab treatment
Trojano, M.
Butzkueven, H.
Kappos, L.
Wiendl, H.
Spelman, T.
Pellegrini, F.
Chen, Y.
Dong, Q.
Koendgen, H.
Belachew, S.
MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 562 - 563
[24] LONG-TERM LYMPHOCYTAPHERESIS IN PROGRESSIVE MULTIPLE-SCLEROSIS
ROSEN, AD
HAMBURGER, MI
PLASMA THERAPY & TRANSFUSION TECHNOLOGY, 1986, 7 (02): : 227 - 230
[25] Long-term escalation therapy with natalizumab in paediatric and adolescent multiple sclerosis
Bayas, A.
Pitarokoili, K.
Penzien, J.
Gold, R.
Hellwig, K.
MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S70 - S70
[26] Natalizumab in paediatric multiple sclerosis: long-term results of 55 cases
Ghezzi, A.
Pozzilli, C.
Moiola, L.
Morra, V. Brescia
Grimaldi, L. M. E.
Lus, G.
Rinaldi, F.
Rocca, M. A.
Trojano, M.
Bianchi, A.
Filippi, M.
Comi, G.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 301 - 302
[27] Progression to disability milestones in multiple sclerosis with long-term natalizumab treatment
Trojano, Maria
Butzkueven, Helmut
Kappos, Ludwig
Wiendl, Heinz
Spelman, Tim
Pellegrini, Fabio
Pellegrini, Fabio
Dong, Qunming
Kondgen, Harold
Belachew, Shibeshih
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP2 - NP2
[28] Propensity-matched analysis of long-term clinical results after ostial circumflex revascularisation
Espejo-Paeres, Carolina
Vedia, Oscar
Wang, Lin
Hennessey, Breda
Mejia-Renteria, Hernan
McInerney, Angela
Nombela-Franco, Luis
Nunez-Gil, Ivan Javier
Macaya-Ten, Fernando
Salinas, Pablo
Tirado, Gabriela
Fernandez-Ortiz, Antonio Ignacio
Gonzalo, Nieves
Escaned, Javier
Jimenez-Quevedo, Pilar
HEART, 2023, 109 (17) : 1302 - 1309
[29] A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod (vol 14, pg 1, 2021)
Salter, Amber
Lancia, Samantha
Cutter, Gary
Marrie, Ruth Ann
Lewin, James B.
Fox, Robert J.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
[30] Long-Term Survival After Carotid Endarterectomy and Carotid Stenting: A Propensity-Matched Analysis
Columbo, Jesse A.
Martinez-Camblor, Pablo
MacKenzie, Todd A.
Staiger, Douglas O.
Kang, Ravinder
Goodney, Philip P.
O'Malley, Alistair J.
JOURNAL OF VASCULAR SURGERY, 2017, 66 (02) : E10 - E11

← 1 2 3 4 5 →